Abstract
It is widely accepted that Aβ42 aggregation is a central event in the pathogenesis of Alzheimers disease. Aβ42 oligomers and fibrils cause the breakdown of neural circuits, neuronal death and eventually dementia. There are a number of physiological molecules that can protect Aβ42 from aggregation. Promoting such protective molecules and mechanisms against Aβ42 aggregation may be a novel direction in AD drug discovery. One of the most striking protective molecules is none other than Aβ40, which inhibits Aβ42 aggregation in a specific and dosage dependent manner. Aβ40 is a critical, built-in mechanism against Aβ42 aggregation. A number of other molecules and mechanisms also inhibit Aβ42 aggregation, such as heat shock proteins, L-PGDS, heme and methionine oxidation. The relevance of these protective mechanisms to AD pathogenesis and intervention is discussed.
Keywords: Amyloid-β peptide (Aβ), Alzheimer's disease (AD), protection, Aβ42 aggregation, Aβ40, NMR, heat shock protein, L-PGDS, heme, methionine oxidation
Current Alzheimer Research
Title: Protection Mechanisms Against Aβ42 Aggregation
Volume: 5 Issue: 6
Author(s): Y. Yan and C. Wang
Affiliation:
Keywords: Amyloid-β peptide (Aβ), Alzheimer's disease (AD), protection, Aβ42 aggregation, Aβ40, NMR, heat shock protein, L-PGDS, heme, methionine oxidation
Abstract: It is widely accepted that Aβ42 aggregation is a central event in the pathogenesis of Alzheimers disease. Aβ42 oligomers and fibrils cause the breakdown of neural circuits, neuronal death and eventually dementia. There are a number of physiological molecules that can protect Aβ42 from aggregation. Promoting such protective molecules and mechanisms against Aβ42 aggregation may be a novel direction in AD drug discovery. One of the most striking protective molecules is none other than Aβ40, which inhibits Aβ42 aggregation in a specific and dosage dependent manner. Aβ40 is a critical, built-in mechanism against Aβ42 aggregation. A number of other molecules and mechanisms also inhibit Aβ42 aggregation, such as heat shock proteins, L-PGDS, heme and methionine oxidation. The relevance of these protective mechanisms to AD pathogenesis and intervention is discussed.
Export Options
About this article
Cite this article as:
Yan Y. and Wang C., Protection Mechanisms Against Aβ42 Aggregation, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898460
DOI https://dx.doi.org/10.2174/156720508786898460 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review
Current Drug Targets Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model
Current Alzheimer Research Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Current Pharmaceutical Design Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews Executive Function and Diabetes Mellitus - A Stone Left Unturned?
Current Diabetes Reviews Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Delayed Neuroleptic Malignant Syndrome Associated with the Use of Low Dose Risperidone in Conjunction with Cholinergic Drugs-the Dangers of Polypharmacy in the Elderly
Current Drug Therapy Mini-Mental Parkinson (MMP) as a Dementia Screening Test: Comparison with the Mini-Mental State Examination (MMSE)
Current Aging Science Oestradiol Signalling in the Hippocampus
Current Neuropharmacology Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry AMPK Function in Aging Process
Current Drug Targets Oxidative Damage, Protein Synthesis, and Protein Degradation in Alzheimers Disease
Current Alzheimer Research Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology